Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pretomanid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : TB Alliance
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the partnership, Remington will commercialize the anti-tuberculosis medicine, pretomanid as part of the all-oral, six-month BPaL and BPaLM regimens for treatment of drug-resistant TB (comprised of bedaquiline, pretomanid, and linezolid) in Pakistan...
Product Name : Pretomanid-Generic
Product Type : Antibiotic
Upfront Cash : Undisclosed
August 14, 2023
Lead Product(s) : Pretomanid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : TB Alliance
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Pretomanid,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Partnership
TB Alliance and Lupin Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB
Details : Lupin intends to commercialize the anti-tuberculosis (TB) medicine, Pretomanid, in approximately 140 countries and territories, including many of the highest TB burden countries around the world.
Product Name : PA-824
Product Type : Antibiotic
Upfront Cash : Undisclosed
June 09, 2021
Lead Product(s) : Pretomanid,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Pretomanid,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The new drug was authorised as part of a three-drug, six month, all-oral regimen for the treatment of adults with extensively drug-resistant TB (XDR-TB) or multidrug-resistant TB (MDR-TB) who are treatment-intolerant or non-responsive.
Product Name : PA-824
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 08, 2020
Lead Product(s) : Pretomanid,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pretomanid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : TB Alliance
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details :
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
January 16, 2020
Lead Product(s) : Pretomanid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : TB Alliance
Deal Size : Undisclosed
Deal Type : Licensing Agreement